Drugs / CD30+ CAR T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07575893 | Oct 2026 → Dec 2031 expected | classic Hodgkin lymphoma | New York Medical College | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD30+ CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07575893 ↗ |
| Modality | Cell therapy | “autologous CD30 CAR T-cells” NCT07575893 ↗ |